復星國際2024年總收入1921.4億元,產業運營利潤49億元
2025年3月30日,復星國際(00656. HK)公佈2024年度業績,總收入人民幣1921.4億元,其中四大核心子公司豫園股份、復星醫藥、復星葡萄牙保險、復星旅文總收入人民幣1346.5億元,佔集團總收入比重達70.1%,資產底盤穩健。2024年,集團產業運營利潤達到人民幣49億元,運營基本面穩定。剔除一次性非現金賬面減值因素影響,歸屬於母公司股東之利潤約為人民幣7.5億元。報吿期內,集團海外收入佔總收入比例達49.3%,同比增長6.2%,全球化業務成為復星新一輪增長引擎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.